MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
NantPharma
Attachments
nantpharma | Development and manufacturing of superior quality, injectable pharmaceuticals.
Parents
Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
Industry: Southern California
Venture Capital: Series A
Children
2012: Blackstone Invests $125 Million in Nantpharma, A Nantworks Company (2012)
Addressing the unmet needs of critically ill patients.
Building an integrated evidence-based, genomically-informed, personalized approach to the delivery of care and the development of next generation diagnostics and therapeutics.
Dr. Patrick Soon-Shiong, has previously founded two successful pharmaceutical companies
His biopharmaceutical company, Abraxis Bioscience, developed the world’s first protein nanotechnology cancer drug transporter for breast cancer and now is in trials for pancreatic and lung cancer.
In January 2012, it announced the acquisition and redevelopment of a former Pfizer facility in Terre Haute, Indiana
Patrick Soon-Shiong, Ph.D, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio, Chair of AAHI’s Board of Directors, CEO, Nantworks, CEO Abraxis Health and Executive Director UCLA Wireless Health Institute- Philanthropist: Medical Technology (2023)
Products Include High Quality, Biologically Derived Pharmaceuticals
The injectable drug company he led, APP Pharmaceuticals, was the nation’s only safe source of heparin during the supply crisis in 2008, NantPharma